Biochem/physiol Actions
TMI-1 (WAY-171318) is potent inhibitor of disintegrin metalloenzyme 17 (ADAM17) also known as the tumor necrosis factor-α (TNF-α) converting enzyme (TACE), and matrix metalloprotease (MMP). TMI-1 potently inhibits LPS-induced TNF-α secretion in human primary monocytes, and human whole blood. TMI-1 selectively induces caspase-dependent apoptosis in triple negative (TN) and ERBB2-overexpressing breast tumor cell lines.
Legal Information
Pfizer is a registered trademark of Pfizer, Inc.
Sold for research purposes under agreement from Pfizer Inc.
Other Notes
This compound was developed by Pfizer for Cytokines & Growth Factors research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.
Packaging
5 mg in glass bottle
| Colour | white to beige |
|---|---|
| Quality Level | 100 |
| InChI key | CVZIHNYAZLXRRS-HNNXBMFYSA-N |
| InChI | 1S/C17H22N2O5S2/c1-4-5-11-24-13-6-8-14(9-7-13)26(22,23)19-10-12-25-17(2,3)15(19)16(20)18-21/h6-9,15,21H,10-12H2,1-3H3,(H,18,20)/t15-/m0/s1 |
| Manufacturer | SIGMA-ALDRICH |
| Form | powder |
| Assay | ≥98% (HPLC) |
There are no downloads for this product.
